office of the general counsel b-282318 april 1 , 1999 the honorable james m. jeffords chairman the honorable edward m. kennedy ranking minority member committee on health , education , labor , and pensions united states senate the honorable thomas j. bliley , jr. chairman the honorable john d. dingell ranking minority member committee on commerce house of representatives subject : department of health and human-services , food and drug administration : over-the-counter human drugs ; labeling-requirements pursuant to section 801 ( a ) ( 2 ) ( a ) of title 5 , united states code , this is our report on a major-rule promulgated by the department of health and human-services , food and drug administration ( fda ) , entitled `` over-the-counter human drugs ; labeling-requirements '' ( rin : 0910-aa79 ) . we received the rule on march 19 , 1999 . it was published in the federal register as a final-rule on march 17 , 1999 . 64 fed . reg . 13254 . the final-rule establishes a standardized-format and standardized-content-requirements for the labeling of over-the-counter-drug-products . the final-rule has an announced effective-date of april 16 , 1999 , which is less than the 60-day delay in a major rule's effective-date required by the small business regulatory enforcement fairness act of 1996 . 5 u.s.c § 801 ( a ) ( 3 ) . the fda gives no reason in the rule 's preamble as to why the 60-day delay provision was not met . while the rule has varying-compliance-dates that are much later than the announced effective-date of the rule ( some previously approved products covered by the rule have several years to become compliant with the labeling-requirement ) , we do note gao/ogc-99-36 that products which have drug-marketing-applications approved on or after april 16 , 1999 , must comply upon approval . enclosed is our assessment of the fda 's compliance with the procedural-steps required by section 801 ( a ) ( 1 ) ( b ) ( i ) through ( iv ) of title 5 with respect to the rule . our review indicates that the fda , with the exception of the failure to allow the 60-day delay , complied with the applicable-requirements . if you have any questions about this report , please contact james w. vickers , assistant general counsel at ( 202 ) 512-8210 . the official responsible for gao evaluation-work relating to the department of health and human-services , food and drug administration , is william scanlon , director , health financing and public health-issues . mr. scanlon can be reached at ( 202 ) 512-7114 . robert p. murphy general counsel enclosure cc : ms. jackie white deputy executive secretariat department of health and human-services page 2 gao/ogc-99-36 enclosure analysis under 5 u.s.c . § 801 ( a ) ( 1 ) ( b ) ( i ) - ( iv ) of a major-rule issued by the department of health and human-services , food and drug administration entitled `` over-the-counter human drugs ; labeling-requirements '' ( rin : 0910-aa79 ) ( i ) cost-benefit-analysis the fda performed a cost-benefit-analysis of the final-rule . the analysis-estimates that the one-time-costs of the rule to be about $ 58 million with annual recurring-costs of about $ 11.5 million . the health-benefits could not be quantified by the fda , but fda believes the benefits to be substantial . if the rule prevents 5 percent of the hospitalizations associated with the unintended-consequences of self-medication , the economic-savings could be $ 39 million annually in direct-benefits and $ 52 million annually from indirect-benefits . in addition , the rule is expected to produce more efficient consumer search activities which could lead to time savings valued at $ 19 million to $ 38 million per year . based on the above , the total-benefits of the rule-range from $ 110.5 million to $ 129.6 million per year . ( ii ) agency-actions relevant to the regulatory-flexibility-act , 5 u.s.c . §§ 603-605 , 607 , and 609 the preamble to the final-rule contains the final regulatory-flexibility-analysis conducted by the fda . using the small business-administration 's size-designation for this industry of fewer than 750 employees , fda estimates that 70 percent of the 400 firms in the industry would be considered small-entities . fda finds that the one-time-cost of compliance for each product , estimated to be $ 600 , should be manageable for small-entities even if they manufacture 10 to 20 products that require relabeling at a cost of $ 6,000 to $ 12,000 . the analysis also discusses the alternatives considered such as different-compliance-dates and the reasons for the alternative selected . gao/ogc-99-36 ( iii ) agency-actions relevant to sections 202-205 of the unfunded-mandates reform act of 1995 , 2 u.s.c . §§ 1532-1535 fda has found that the final-rule will not impose a mandate on either state , local , or tribal-governments or the private sector in any one year of $ 100 million or more . ( iv ) other relevant-information or requirements under acts and executive-orders administrative procedure act , 5 u.s.c . §§ 551 et seq . the final-rule was issued using the notice and comment procedures found at 5 u.s.c . § 553 . on february 27 , 1997 , the fda published a notice of proposed-rulemaking in the federal register . 62 fed . reg . 9024 . the fda received over 1,800 comments and discusses the comments and the changes it made to the proposed-rule in the preamble to the final-rule . paperwork reduction act , 44 u.s.c . §§ 3501-3520 the final-rule contains information-collections which are subject to review by the office of management and budget under the paperwork reduction act . the preamble to the final-rule contains the information required by the act , including a description of the collection , the reason for the collection , and an estimate of the annual-burden-hours imposed . fda estimates that the total-burden-hours annually will be 120,578 with 51,336 hours being a one-time-burden . the burden-hours are not higher because , with the varied compliance-dates for the labeling , many manufacturers will be able to change the labels as part of the usual and customary-business-practice of redesigning the labels and therefore no additional-burden is incurred . statutory-authorization for the rule the final-rule was issued-pursuant to the authority of the federal food , drug , and cosmetic act and the public health service act as codified at 21 u.s.c . §§ 321 , 331 , 351 , 352 , 353 , 355 , 358 , 360 , 360b , 360gg-360ss , 371 , 374 , 379e and 42 u.s.c . §§ 216 , 241 , 262 , and 264 . page 2 gao/ogc-99-36 executive-order no . 12866 the final-rule was reviewed by the office of management and budget and determined to be an economically-significant regulatory-action and approved as complying with the order . page 3 gao/ogc-99-36 